Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/68381
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients
Author: Hiwase, D.
Yeung, D.
White, D.
Citation: Expert Review of Hematology, 2011; 4(3):285-299
Publisher: Expert Reviews Ltd
Issue Date: 2011
ISSN: 1747-4086
1747-4094
Statement of
Responsibility: 
Devendra K Hiwase, David T Yeung and Deborah L White
Abstract: Long-term follow-up of clinical studies has demonstrated the efficacy of imatinib therapy in newly diagnosed chronic phase-chronic myeloid leukemia patients (CML). However, recent updates of two separate randomized Phase III studies demonstrated higher complete cytogenetic and major molecular response rates with dasatinib and nilotinib compared with imatinib 400 mg/day. Hence, for newly diagnosed chronic phase-CML patients there are multiple treatment options, including standard-dose imatinib, high-dose imatinib, and combination therapy of imatinib and interferon, dasatinib and nilotinib. This article critically analyzes the current literature and provides guidelines for the management of newly diagnosed CML. Disease and therapy-related prognostic factors, which may aid in the selection of therapeutic strategies to enable optimal treatment outcomes, are discussed. In addition, we provide commentary on the therapeutic options for patients who fail imatinib therapy.
Keywords: CML; dasatinib; imatinib; nilotinib; TKI
Rights: © 2011 Expert Reviews Ltd.
RMID: 0020110916
DOI: 10.1586/ehm.11.19
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.